⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 2, 2025Open Access

Supplementary Figure 1 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Kaushik Varadarajan Christian X. Cruz Pico Kurt W. Evans Maria Gabriela Raso Yasmeen Q. Rizvi Xiaofeng Zheng Dhruv Chachad Timothy P. DiPeri Bailiang Wang Stephen M. Scott Ming Zhao Argun Akçakanat Antje M. Wengner Timothy A. Yap Funda Meric‐Bernstam

View Full Paper

Ask AI

Bookmark

Share

Key Points

Elimusertib shows differential response at varying dosages in tumors, hinting at its therapeutic potential.
Utilizing 40 mg/kg of elimusertib outperformed the 20 mg/kg dosage in inducing a better therapeutic response.
Analysis of response to the ATR kinase inhibitor was conducted between two dosage levels, showcasing effectiveness.
These findings underscore the significance of dosing in response to targeted therapies for tumors with genomic alterations.

Implication

Comparison of elimusertib at 40 mg/kg versus 20 mg/kg reveals its efficacy in tumors, indicating potential for targeted treatment strategies.

Abstract

Supplementary Figure 1: Comparison of response to elimusertib 40 mg/kg vs 20 mg/kg.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Varadarajan et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd02894 https://doi.org/10.1158/1535-7163.30028678

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 5 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
2Supplementary Figure 4 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
3Supplementary Figure 3 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
4Supplementary Figure 6 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
5Supplementary Figure 10 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025